MusclePharm market cap is $18.1 m, and annual revenue was $102.16 m in FY 2017

MusclePharm Gross profit (Q3, 2018)8.8 M

MusclePharm Gross profit margin (Q3, 2018), %32.1%

MusclePharm Net income (Q3, 2018)-2 M

MusclePharm EBIT (Q3, 2018)-991 K

MusclePharm Cash, 30-Sep-20181.7 M

MusclePharm EV17.8 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Revenue | 177.4m | 166.9m | 132.5m | 102.2m | |

| (6%) | (21%) | |||

## Cost of goods sold | 77.7m | 121.4m | 109.9m | 88.0m | 71.7m |

## Gross profit | 56.0m | 56.9m | 44.5m | 30.4m | |

| 32% | 34% | 34% | 30% | |

## Sales and marketing expense | 11.8m | 25.3m | 31.2m | 18.0m | 10.1m |

## R&D expense | 1.1m | 4.0m | 4.3m | 1.9m | 642.0k |

## General and administrative expense | 7.2m | 13.4m | 19.4m | 15.9m | 12.1m |

## Operating expense total | 20.1m | 42.7m | 106.9m | 53.1m | 37.6m |

## EBIT | (14.3m) | (19.4m) | (49.9m) | (8.7m) | (7.2m) |

| (11%) | (30%) | (7%) | (7%) | |

## Interest expense | 783.3k | ||||

## Interest income | 1.4m | ||||

## Pre tax profit | (13.8m) | (51.8m) | (3.2m) | (10.8m) | |

## Income tax expense | (115.5k) | 33.0k | 105.0k | 318.0k | (108.0k) |

## Net Income | (17.7m) | (13.8m) | (51.9m) | (3.5m) | (11.0m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Cash | 5.4m | 1.0m | 7.1m | 4.9m | 6.2m |

## Accounts Receivable | 13.7m | ||||

## Inventories | 15.8m | 1.7m | 12.5m | 8.6m | 6.5m |

## Current Assets | 44.5m | 46.4m | 47.3m | 28.8m | 30.5m |

## PP&E | 7.8m | 6.7m | 3.2m | 1.8m | |

## Total Assets | 52.2m | 66.4m | 63.8m | 34.1m | 33.8m |

## Accounts Payable | 28.4m | 27.8m | 39.7m | 9.6m | 11.7m |

## Current Liabilities | 32.4m | 42.8m | 67.3m | 38.4m | 28.5m |

## Long-term debt | 2.5m | 8.0m | 3.0m | 3.0m | |

## Total Debt | 2.5m | 3.0m | 3.0m | ||

## Total Liabilities | 32.4m | 73.8m | 39.0m | 46.4m | |

## Additional Paid-in Capital | 103.1m | 129.1m | 147.6m | 156.3m | 159.6m |

## Retained Earnings | (81.8m) | (95.7m) | (147.5m) | (151.0m) | (162.0m) |

## Total Equity | 19.7m | 23.4m | (4.9m) | (12.5m) | |

## Financial Leverage | 2.6 x | 2.8 x | -7 x | -2.7 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Net Income | (17.7m) | (13.8m) | (51.9m) | (3.5m) | (11.0m) |

## Depreciation and Amortization | 709.0k | 1.3m | 1.8m | 1.6m | 1.1m |

## Accounts Receivable | (10.7m) | (2.6m) | (5.6m) | 7.3m | (4.6m) |

## Inventories | 2.0k | 5.9m | (480.0k) | 2.1m | |

## Accounts Payable | 23.1m | 14.2m | (20.8m) | 2.0m | |

## Cash From Operating Activities | (10.0m) | (4.1m) | 5.5m | (15.1m) | (5.1m) |

## Purchases of PP&E | (1.9m) | (4.1m) | (1.5m) | (508.0k) | (37.0k) |

## Cash From Investing Activities | (3.5m) | (1.6m) | (3.0m) | 5.4m | (37.0k) |

## Long-term Borrowings | (4.4m) | (17.0k) | |||

## Cash From Financing Activities | 18.9m | 1.4m | 3.7m | 7.5m | 6.4m |

## Interest Paid | 411.4k | 158.0k | 527.0k | 1.6m | 2.4m |

## Income Taxes Paid | 87.4k | 301.0k | 77.0k | 218.0k | 106.0k |

USD | Y, 2018 |
---|---|

## EV/EBIT | -18 x |

## Debt/Equity | -0.1 x |

## Debt/Assets | 0.1 x |

## Financial Leverage | -1.6 x |